⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22271054 | 0.82 | LMNA (0.37) | — | |
| SCHEMBL363319 | 0.81 | — | — | |
| SCHEMBL882027 | 0.81 | — | — | |
| SCHEMBL10265108 | 0.75 | — | — | |
| SCHEMBL30578987 | 0.74 | — | — | |
| SCHEMBL29434174 | 0.74 | — | — | |
| SCHEMBL19341243 | 0.74 | — | — | |
| SCHEMBL14134960 | 0.74 | — | — | |
| SCHEMBL390280 | 0.74 | — | — | |
| SCHEMBL13632702 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20230399302-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS | NATIONAL INSTITUTES OF HEALTH | 2023-12-14 | — | — | US | disclosed |
| WO-2023169573-A1 | POLθ INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-116730979-A | Pol theta inhibitor | 武汉人福创新药物研发中心有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-3686199-B9 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2022-12-07 | — | — | EP | disclosed |
| EP-3611174-B1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2022-06-08 | — | — | EP | disclosed |
| EP-3686199-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-3611174-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | Medshine Discovery Inc. (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170369443-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| EP-2244577-B1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8273737-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273737-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2009094279-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |